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Abstract Without prophylaxis, patients ubjected to ma- 
jor abdominal surgery have a risk of deep vein thrombosis 
of approximately 30%, while the rate varies between 40% 
and 60% in orthopedic surgery. The reasons for this dis- 
crepancy are not completely understood. The present study 
was designed to compare the pre- and postoperative be- 
havior of different coagulation and fibrinolysis parameters 
in patients undergoing both types of surgery, receiving low 
molecular weight heparin prophylaxis. Samples were taken 
before operation and on postoperative days 1,3, and 7. The 
following parameters were assessed: prothrombin frag- 
ment 1+2, thrombin-antithrombin III complexes, fibrino- 
peptide A, tissue plasminogen activator, plasminogen ac- 
tivator inhibitor, plasmin-c~__-antiplasmin complexes, and 
fibrin degradation products. We found a significant in- 
crease in the clotting markers postoperatively compared 
with preoperative values (P<0.05), both in abdominal and 
orthopedic surgery, indicating a marked hemostatic acti- 
vation which remained until postoperative day 7. A signif- 
icant increase in plasminogen activator inhibitor (P<0.01) 
and a decrease in tissue plasminogen activator and plas- 
min-%-antiplasmin complexes was also observed early 
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after operation. The plasminogen activator inhibitor activ- 
ity decreased, while tissue plasminogen activator and plas- 
min-a2-antiplasmin levels increased significantly on days 3 
and 7 (P<0.05). Fibrin degradation products ignificantly 
increased throughout the postoperative period (P<0.01). 
Preoperatively, we found higher plasminogen activator in- 
hibitor activity and lower tissue plasminogen activator and 
plasmin-c~__-antiplasmin complexes (P<0.05) in patients 
undergoing hip replacement compared with abdominal sur- 
gery. Fibrin degradation products were also significantly 
lower on postoperative day 3 in patients undergoing hip 
i'eplacement (P<O.O1). We suggest that the lower preoper- 
ative fibrinolytic activation observed in patients undergo- 
ing orthopedic surgery compared with abdominal surgery 
might have pathophysiological consequences. Our results 
also indicate that the hemostatic activation persists beyond 
the 7th postoperative day despite prophylaxis. 
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Introduction 
During surgery, several factors such as venous tasis, vas- 
cular damage, and hemostatic changes may predispose to 
venous thrombosis n the lower extremities, leading to pul- 
monary embolism (PE) [ 1, 2]. The incidence of deep vein 
thrombosis (DVT) after abdominal surgery in patients over 
40 years varies between 10% and 30%, while fatal PE has 
been reported in 0.5%- 1% if no prophylaxis i  used. Fol- 
lowing major elective orthopedic surgery, more than 50% 
of patients will develop DVT, and approximately 3%-  5% 
develop symptomatic PE, which remains the major cause 
of postoperative d ath (0.5%-2%) [3, 4]. A considerable 
risk for DVT still remains (12%-30%), despite prophy- 
laxis treatment [5-8]. To date, the factors contributing to 
the higher DVT incidence after orthopedic ompared with 
abdominal surgery are not well established. Advanced age, 
prolonged bed rest, and major tissue injury, with subse- 
quent changes in the coagulation and fibrinolytic mecha- 
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nisms, could explain some of the observed differences 
between the types of surgery [9, 10]. 
Advances in our knowledge of the biochemistry of he- 
mostasis have led to the development of sensitive and spe- 
cific assays to identify prethrombotic states. These include 
activation peptides and enzyme- inhib i tor  complexes re- 
leased during the activation of the coagulation and fibrin- 
olytic systems. Prothrombin fragment I+2 (Fl+2),  throm- 
bin-ant i thrombin complexes (TAT), and fibrinopeptide A 
(FPA) are sensit ive markers of thrombin formation and 
subsequently of clotting activation, whereas tissue-type 
plasminogen activator (t-PAL its inhibitor (PAI-1), plas- 
min-ant ip lasmin complexes (PAP), and fibrin degradation 
products (FDP) are useful for detecting an imbalance in 
the fibrinolytic mechanism [ 1 1 - 13]. 
The aim of this study was to investigate whether differ- 
ences in the pre- and postoperative plasma levels of sev- 
eral hemostatic activation markers could explain the higher 
thrombotic risk associated with orthopedic versus abdom- 
inal surgery in patients receiving low molecular weight 
heparin prophylaxis. 
Patients and methods 
Patients 
Thirty patients (20 males, 10 females) subjected to major abdominal 
surgery, with a mean age of 54.4__.11.6 years (range 29-71), and 
25 patients (15 males, 10 females) undergoing total hip replacement, 
with a mean age of 60.8-+12.6 years (range 39-80), were included 
in the study. Indications for abdominal surgery were as follows: co- 
lon malignancy (n= 12), gastric malignancy (n=7), cholecystecto- 
my (n=9), endometrium adenocarcinoma (n= 1), and hepatectomy 
(n= 1). 
All patients received preoperatively low molecular weight hep- 
arin in doses adjusted to the thrombotic risk until postoperative day 7: 
Fragmin (Pharmacia. Sweden) 2,500 U anti Xa/d in patients under- 
going abdominal surgery and Enoxaparin (Rh6ne Poulenc Rorer, 
France) 40 mg in those undergoing hip replacement. The prophylax- 
is continued for 7 days or until discharge from hospital. Patients with 
a past history of a bleeding diathesis, thromboembolism within the 
past 3 months, or anticoagulant use in the previous 6weeks were ex- 
cluded from the study. Oral informed consent was obtained from all 
patients. 
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measured with the ELISA FPA kit (Hemodiagnostica-Stago, France), 
which is a competitive enzyme immunoassay [16]. 
t-PA was determined using the Coatest BIA tPA kit (Chromogen- 
ix, Sweden), a bioimmunoassay which determines free t-PA [17]. 
Briefly, 50 gl of acidified sample was applied to the wells of a mi- 
crotiter plate coated with a monoclonat nti t-PA antibody which does 
not block the active site of t-PA, so its activity can be measured ina 
spectrophotometer by adding a chromogenic substrate for ptasmin. 
PAI-1 was measured by an amidolytic assay, using the Coatest 
PAI kit (Chromogenix) [18]. PAP were measured with the ELISA 
previously described in our laboratory by Montes et al. [19]. FDP 
were measured with the Fibrinostika FDP kit (Organon Teknika, The 
Nedertands), with a specific anti D-dimer monoclonal ntibody [20]. 
Statistical analysis 
Mean values and standard errors were calculated. The two-tail Wil- 
coxon signed rank test was used for the comparison of post- and pre- 
operative samples. To test for significant differences between ab- 
dominal and orthopedic surgery, the Mann-Whitney U test was used. 
A value of P<0.05 was considered significant. 
Results 
The study included 55 patients of both sexes who under- 
went abdominal  surgery (n = 30) and total hip replacement 
(n=25) ,  with no signif icant differences in the mean age 
between the groups. Samples were taken preoperatively 
and on postoperative days 1, 3, and 7 to assess different 
coagulat ion and f ibrinolysis parameters. 
Preoperatively, the levels of the different clotting mark- 
ers were slightly increased in orthopedic compared with 
abdominal  surgery patients, although no signif icant differ- 
ences were found. However, the preoperative PAL1 activ- 
ity was signif icantly higher (P<0.05),  while t-PA activity 
and PAP complexes were lower (P<0.05) in patients under- 
going hip replacement compared with abdominal  surgery 
(Table 1). FDP were more reduced in orthopedic patients, 
although without signif icant differences compared with the 
abdominal  group (P=0.07) .  
Figure 1 shows the postoperative evolut ion of the dif- 
ferent clotting activation markers in patients undergoing 
abdominal  and orthopedic surgery in relation to preopera- 
Blood collection 
Blood samples were drawn before operation and on postoperative 
days 1, 3, and 7. Venous blood was collected between 8and 9 a. m., 
with patients at rest, in siliconized vacutainer tubes containing 
0.13 M trisodium citrate. Samples were kept on ice until centrifuga- 
tion at 3,000 g for 15 min. Aliquots of platelet-poor plasma were 
stored at -70 ~ For t-PA determination, blood was collected in Stab- 
ilyte tubes (Biopool, Sweden) in order to avoid inhibitor interfer- 
ence. All preoperative samples were taken before prophylaxis ad- 
ministration. 
Assays 
Prothrombin F 1 +2 was assayed by ELISA, using the commercial En- 
zygnost F1+2 (Behringwerke, Germany) [14]. TAT were measured 
using the ELISA kit Enzygnost TAT (Behringwerke) [15]. FPA was 
Table 1 Comparison of preoperative l vels of hemostatic markers 
in surgical patients (mean_+SEM) (F1 +2 prothrombin fragment 1+2, 
TAT thrombin-antithrombin complexes, FPA fibrinopeptide A, 
t-PA tissue plasminogen activator, PAl-1 plasminogen activator in- 
hibitor, PAP plasmin-antiptasmin complexes, FDP fibrin degrada- 
tion products) 
Parameters Abdominal Orthopedic P 
surgery surgery 
F 1 +2 (nmol/1) 1.26_+0.10 1.56_+0.19 
TAT (gg/l) 4.55_+0.77 6.53_+1.90 
FPA (gg/l) 1.28_+0.10 1.66_+0.21 
t-PA (U/ml) 0.28_+0.04 0.15_+0.03 
PAI- 1 (U/ml) 15 .96-+1.71 20.36_+2.49 
PAP (p.g/1) 507.59-+37.29 320.23_+29.22 
FDP (gg/1) 585.37-+103.83 365.68-+48.44 
NS 
NS 
NS 
<0.05 
<0.05 
<0.001 
NS 
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Fig. 1 Evolution of prothrombin fragment 1+2 (Fl+2) (a), throm- 
bin-antithrombin (TAT) complexes (b), and fibrinopeptide A (FPA) 
(e) throughout the postoperative p riod in orthopedic (---I---) and 
abdominal ( - -T - - )  surgery. Mean_+SEM is given. * P<0.05, 
9 * P<0.01, and *** P<0.0001 with respect to baseline 
rive levels. A similar increase in all clotting markers was 
observed in both groups with respect o baseline, persist- 
ing on day 7 (P<0.05). Maximum TAT levels were ob- 
served on postoperative day 1 in both groups (P<0.01), 
while F l+2 and FPA showed the highest values on day 3 
(P<0.05) in relation to the preoperative l vels. 
Among the fibrinolytic parameters analyzed we found 
a significant increase in PAI-1 activity on postoperative 
day I (P<0.05) and a decrease on days 3 and 7 in relation 
to the preoperative l vels in both abdominal and orthope- 
dic surgery. A slight reduction of t-PA activity was ob- 
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Fig. 2 Evolution of plasminogen activator inhibitor (PAl-l) activ- 
ity (a) and tissue plasminogen activator (t-PA) (b) throughout the 
postoperative p riod in orthopedic (---I---) and abdominal ( - -Y- - )  
surgery. Mean_+_SEM isgiven. * P<0.05 and ** P<0.01 with respect 
to baseline 
served early after the operation and this increased signifi- 
cantly on day 7 (P<0.05) (Fig. 2). The concentration of 
PAP complexes decreased significantly on day 1 (P<0.05) 
compared with preoperative levels in both groups, fol- 
lowed by a marked increase on days 3 and 7 (P<0.01) 
(Fig. 3). No significant differences in the changes could be 
demonstrated between abdominal and orthopedic surgery. 
As shown in Fig. 3, FOP levels increased markedly 
throughout the postoperative period in both types of sur- 
gery (P<0.05), but the generation of FDP was significantly 
reduced on postoperative day 3 in patients undergoing hip 
replacement compared with abdominal surgery (P<0.01). 
Finally, no correlations between the changes in hemostatic 
parameters and the patients' age were observed. 
Discussion 
Sensitive markers for coagulation and fibrinolysis activa- 
tion were assessed pre- and postoperatively in patients 
undergoing abdominal and orthopedic surgery. Before sur- 
gery no differences in the clotting markers were observed 
between the groups9 However, the PAI-1 activity was 
higher and t-PA and PAP complexes were lower in patients 
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undergoing hip replacement compared with abdominal sur- 
gery, suggesting a reduced preoperative fibrinolytic activ- 
ity in the orthopedic group. It is interesting to note the 
higher PA[-I activity in orthopedic patients, despite the 
number of cancer patients included in the abdominal group, 
which is a clinical condition classically associated with an 
increase in the inhibitor levels [21, 22]. Previous studies 
have reported a direct relationship between reduced pre- 
operative fibrinolytic activity and the development ofpost- 
operative DVT [23]. It has also been demonstrated that 
PAI-1 and t-PA levels may be predictive for the develop- 
ment of thromboembolic episodes after different ypes of 
surgery [24 - 26]. 
A significant increase of all clotting markers during the 
postoperative period compared with preoperative levels 
was observed, showing a similar degree of clotting activa- 
tion in both groups of patients. Our results confirm that a 
significant activation of the coagulation system takes place 
after surgery [27]. It has also been suggested that the in- 
crease in these clotting markers may be predictive for the 
development of postoperative thrombosis, thus being use- 
ful in the detection of a prethrombotic state after surgery 
[281. 
Impaired fibrinolytic activity characterized by a signif- 
icant,increase in PAI- 1 and a reduction in t-PA was found 
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immediately after operation, followed by a marked inhib- 
itor decrease until day 7 in both types of surgery. Reduced 
fibrinolytic activity is a well-known feature of the early 
postoperative state and has been referred to as fibrinolytic 
shut-down [29-  31 ]. A significant increase in FDP was also 
found postoperatively in both types of surgery, indicating 
fibrinolysis activation secondary to fibrin formation and 
plasmin generation, which was demonstrated by the PAP 
increase on days 3 and 7. However, the FDP generation 
was less evident in patients undergoing hip replacement. 
Some authors have suggested that FDP levels may be use- 
ful for predicting postoperative DVT [32-34].  It is un- 
likely that the observed fibrinolysis differences between 
both types of surgery could be attributed to changes in- 
duced by the different prophylactic dose, since a clear 
effect of low molecular weight heparin on fibrinolysis has 
not been demonstrated in vivo [35, 36]. 
Advanced aged could also account for some of the ob- 
served changes indicating activation of the hemostatic 
mechanism [37]. However, no correlations between the 
changes in the hemostatic parameters and the patients' age 
were demonstrated. The levels of the clotting markers re- 
mained elevated on day 7 despite prophylaxis with low mo- 
lecular weight heparin. The possible benefit of prolonged 
prophylactic treatment on the basis of a reduction in the 
plasma levels of these markers needs to be carefully eval- 
uated [38]. 
In conclusion, the impairment of fibrinolysis seems to 
be more evident in orthopedic than abdominal surgery; this 
might be an additional risk factor for thrombosis in the for- 
mer group and might partially explain the different hrom- 
botic tendency between the types of surgery. Additional 
studies are needed to confirm whether these fibrinolytic 
differences might be of significance for postoperative 
thrombosis, using objective diagnostic methods to evalu- 
ate DVT. 
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